Three distinguished oncologists have joined Washington Cancer Institute in the past several months.
Emily E. Carmody Soni, MD
Emily E. Carmody Soni, MD, is an orthopaedic oncologist specializing in the treatment of musculoskeletal tumors in both adults and children.
Dr. Carmody Soni received her medical degree with a distinction in research from the University of Rochester School of Medicine and Dentistry in Rochester, and completed her residency at the University of Florida, in Gainesville. Following her residency, Dr. Carmody Soni completed an orthopaedic surgery oncology fellowship at the University of Florida. She has dedicated herself to research in the fields of orthopaedic surgery, and the treatment of bone and soft tissue sarcomas.
Dr. Carmody Soni has received numerous awards in recognition of her research in orthopaedic oncology, including the award for Outstanding Distinction in Research from the Associated Medical Schools of New York. She has published her work in many peer-reviewed journals and has presented her research at many national meetings. Currently she is involved in both clinical and basic science research at MedStar Washington Hospital Center and Georgetown University.
Washington Cancer Institute’s Orthopaedic Oncology Center has expertise in minimally invasive biopsy methods, complex tumor resection, complex revision or reconstructive surgery, and shoulder and pelvic girdle surgery. We offer a full range of consultative services to referring physicians.
Dr. Carmody Soni’s Special Interests:
Our experienced team maintains communication with the referring physician during the patient care process and refers the patient back to the physician following treatment.
Pia M. Herbolsheimer, MD, PhD
Pia M. Herbolsheimer, MD, PhD, is a medical oncologist who specializes in breast cancer. She has extensive experience in molecular biology, focusing on cancer genetics. Her goal is to translate basic scientific knowledge into clinical applications, such as new targeted therapies. She is conducting investigator-initiated and large multicenter clinical trials in breast cancer.
Dr. Herbolsheimer has published extensively on breast, ovarian and prostate cancer genetics. More recently, she has published results on clinical trials in breast cancer. She received her medical and doctorate degrees from the University of Oulu in Finland.
Her postdoctoral work included a research fellowship at the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH), where she conducted gene identification studies in breast, ovarian and prostate cancers. She was also a research fellow at the Translational Genomics Research Institute (TGen).
Dr. Herbolsheimer completed her training at MedStar Georgetown University Hospital, including an internship and residency in internal medicine and a fellowship in hematology and oncology.
Sekwon Jang, MD
Sekwon Jang, MD, joins Washington Cancer Institute as a hematologist and medical oncologist, specializing in diagnosing and treating melanoma.
Dr. Jang received his medical degree from Seoul National University College of Medicine in Seoul, Korea, and completed his residency at the Albert Einstein Medical Center in Philadelphia. Following his residency, Dr. Jang completed his fellowship in hematology, oncology and transplantation at the University of Minnesota in Minneapolis. He is certified by the American Board of Internal Medicine. In addition to specializing in treating melanoma, Dr. Jang has a special interest in advanced skin cancer and general medical oncology.
In recognition of Dr. Jang’s outstanding research, he has received numerous awards from the American Society of Clinical Oncology and the American Society of Hematology.
Medical Oncology and Hematology Center
The Medical Oncology and Hematology Center at Washington Cancer Institute provides comprehensive treatment for solid tumors and hematologic malignancies. Our medical oncologists and hematologists specialize in treating a variety of cancers. They are nationally recognized leaders in the field of innovative cancer treatments. Our outpatient Infusion Center offers post-discharge chemotherapy continuity. Emergency responses are also available.